NOTCH1 Mutations in Aortic Stenosis: Association with Osteoprotegerin/RANK/RANKL
Table 1
Clinical characteristics of patients in aortic stenosis and control groups.
Patients with M ± SD
Patients with BAV M ± SD
Patients with TAV M ± SD
DNA control group
versus DNA control group
value TAV versus BAV patients
()
()
()
()
Age, years
<0.01
0.9
Gender, m : f
1.3 : 1
1.8 : 1
1 : 1
1 : 1.1
0.5
0.25
BMI, kg/m2
0.48
0.10
Arterial hypertension, (%)
50 (82%)
22 (71%)
28 (93%)
60 (30%)
<0.01
0.05
Systolic BP, mmHg
<0.01
0.11
Diastolic BP, mmHg
<0.01
0.12
Diabetes mellitus, (%)
10 (16)
5 (9.7)
5 (13.3)
3 (1.5)
<0.01
0.97
COPD, (%)
12 (19.7)
5 (16.1)
5 (16.7)
10 (10)
0.67
0.86
Smoking, (%)
14
7 (22.6)
7 (23.3)
102 (51)
<0.01
0.97
Total cholesterol, mmol/l
0.3
0.20
HDL-C, mmol/l
0.46
0.97
LDL-C, mmol/l
0.99
0.63
Triglycerides, mmol/l
0.82
0.85
Medication, (%)
54 (88)
27 (87)
27 (90)
47 (24)
<0.01
0.98
ACE inhibitors /ARB, (%)
22 (36)
13 (41.9)
9 (30)
47 (24)
0.02
0.61
Beta-blockers, (%)
51 (84)
26 (83.9)
25 (83.3)
0
—
0.92
CCB, %
3 (5)
2 (6.5)
1 (3.3)
0
—
0.85
Statins, (%)
36 (59)
18 (58.1)
18 (60)
0
—
0.98
DNA control group: healthy donors, including for control DNA; BMI: body mass index; BP: blood pressure; COPD: chronic obstructive pulmonary disease; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; ARB: angiotensin II receptor blockers; ACE: angiotensin-converting enzyme inhibitors; CCB: calcium-channel blocker. Patients with AS.
